Global Ophthalmology Contract Research Organization (CRO) Market Size To Exceed USD 4.62 Billion By 2033 | CAGR Of 6.95%
July 02, 2024 08:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , July 02, 2024 (GLOBE NEWSWIRE) -- The Global Ophthalmology Contract Research Organization (CRO) Market Size is to Grow from USD 2.36 Billion in 2023 to USD 4.62 Billion by...
Global Medical Biomimetics Market Research 2024: Cardiovascular Biomimetics Innovations, Orthopedic Biomimetics Advancements, Revolutionizing Ophthalmology Biomimetic Technologies
July 02, 2024 07:19 ET
|
Research and Markets
Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Global Medical Biomimetics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
Global Ophthalmoscopes Market Size To Exceed USD 482.31 Million By 2033 | CAGR Of 6.74%
July 01, 2024 10:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , July 01, 2024 (GLOBE NEWSWIRE) -- The Global Ophthalmoscopes Market Size is to Grow from USD 251.2 Million in 2023 to USD 482.31 Million by 2033, at a CAGR of 6.74% during...
Veterinary Ophthalmology Equipment Market Surges to $697M by 2029 | MarketsandMarkets™
July 01, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, July 01, 2024 (GLOBE NEWSWIRE) -- The veterinary ophthalmology equipment market is projected to grow significantly from $485 million in 2024 to approximately $697 million by 2029, with a...
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
July 01, 2024 02:03 ET
|
Samsung Bioepis
PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
June 30, 2024 16:21 ET
|
Pomerantz LLP
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are advised...
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
June 28, 2024 16:04 ET
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
June 28, 2024 07:15 ET
|
F. Hoffmann-La Roche Ltd
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to...
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 28, 2024 06:57 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Dr. Nicolas Biro Joins DLV Vision, Enhancing Oculoplastic Services
June 27, 2024 11:51 ET
|
DLV Vision - Westlake Village
Westlake Village, California, June 27, 2024 (GLOBE NEWSWIRE) -- [Westlake] — DLV Vision, a premier surgical and eye care practice, announces the addition of Dr. Nicolas Biro to their distinguished...